LASSO-AF Clinical Trial Approved for Aegis Medical Innovations' Sierra Ligation System

 

March 22, 2017—Aegis Medical Innovations Inc. announced that it has received investigational device exemption approval from the US Food and Drug Administration to initiate a clinical trial in the United States for the Sierra ligation system, which the company developed in partnership with the Mayo Clinic in Rochester, Minnesota. The Sierra device is being developed for the prevention of stroke in patients with atrial fibrillation (AF).

According to the company, the LASSO-AF clinical trial is an early feasibility study designed to assess the safety and procedural success of Sierra in closing off the left atrial appendage (LAA) using a minimally invasive epicardial approach. The trial will enroll patients if their doctor(s) have determined that they have AF, are at increased risk for developing a stroke, and are not ideal candidates for anticoagulation drug therapy.

The clinical trial is scheduled to begin in the United States in May 2017. The hospital approval process has begun for the trial to take place at Mount Sinai in New York, New York; the Mayo Clinic; Houston Methodist Hospital in Houston, Texas; and Pacific Heart Institution in Santa Monica, California.

In the company's announcement, Vivek Reddy, MD, commented, “For many AF patients, anticoagulants are used to reduce the risk of stroke. One of the downsides of these drugs is that they can result in life-threatening bleeding. Aegis has developed a minimally invasive, nonvascular LAA closure device that is designed to protect the patient from AF-related stroke without taking blood thinners. In contrast to vascular treatments, this nonvascular approach does not implant a device inside the heart that might migrate or cause clots in the LAA, thus potentially improving patient safety.” Dr. Reddy is a Mount Sinai Cardiovascular Disease Specialist in New York, New York.

The lead Principal Investigator for LASSO-AF is Sheldon Singh, MD, who is with Sunnybrook Health Sciences Center in Toronto, Ontario. Dr. Singh stated, “This study will confirm the safety of the Sierra device for patient use and will lay a solid foundation for future efforts to demonstrate that Sierra can prevent stroke in AF patients and eliminate the need to take blood thinners for stroke prevention.”

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Cardiac Interventions Today

Cardiac Interventions Today is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007, with its launch issue focusing on the state of coronary drug-eluting stent use. Each edition will cover a variety of topics in a flexible format that includes articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's cardiology practices.